Table 1.

Descriptive clinical baseline data of COVID-19 patients (n = 412) treated in a German tertiary care hospital (a). Comorbidities and course of COVID-19 are shown in part (b).

(a)		(b)
Parameter	Data	Parameter	Data
Sex Female/male	199/213 (48.3%/51.7%)	Obesity no/yes	324/88 (78.6%/21.4%)
Median age (years)	58 (16–97)	Diabetes mellitus no/yes	314/97 (76.4%/23.6%)
Body mass index (kg/m2)	27.7 (17.3–50.5)	Smoking no/yes	359/53 (87.1%/12.9%)
Vaccination status No vaccination 1st vaccination 2nd vaccination 1st booster 2nd booster	367 (89.1%) 19 (4.6%) 23 (5.6%) 3 (0.7%) 0 (0%)	Lung diseases no/yes	338/74 (82%/18%)
Recovery rate no/yes	409/3 (99.3%/0.7%)	Cardiovascular diseases no/yes	189/223 (45.9%/54.1%)
Median Ct-value (S-gene) (E-gene) (RdRP-gene) (N-gene)	22 (7–38) 23 (10–37) 24 (7–39) 25 (11–287)	Neuropsychiatric diseases no/yes	328/84 (79.6%/20.8%)
Fever (≥38 °C) no/yes	319/79 (80.2%/19.8%)	At least two comorbidities no/yes	198/214 (48.1%/51.9%)
Dysnosomie no/yes	326/86 (79.1%/20.9%)	Staging by Siddiqi and Mehra Stage I Stage IIA Stage IIB Stage III	89 (21.6%) 52 (12.6%) 223 (54.1%) 49 (11.9%)
Breathing rate median	19 (8–50)	WHO clinical progression scale I II III IV	93 (22.6%) 211 (51.2%) 54 (13.1%) 55 (13.3%)
Oxygen saturation median percentage	97 (40–100)	COVID-19 pneumonia no/yes	104/307 (25.3%/74.7%)
Days with symptoms before admission median	6 (1–22)	Intensive care unit (ICU) no/yes median days on ICU	312/100 (75.7%/24.3%) 9.5 (1–85)
In-patient treatment no/yes	23/389 (5.6%/94.4%)	Deceased with COVID-19 no/yes	357/55 (86.7%/13.3%)
Duration of in-patient treatment median	10 (1–194)	Duration of in-patient treatment median	10 (1–194)
		Breathing support no oxygen via nasal canula high-flow oxygen, non-invasive ventilation intubation ECMO	140 (34%) 179 (43.4%) 56 (13.6%) 26 (6.3% 11 (2.6%)
		Anti-COVID-19 therapy no dexamethasone remdesivir dexamethasone/remdesivir miscellaneous	216 (52.4%) 97 (23.5%) 31 (7.5%) 48 (11.7%) 20 (4.9%)